Table 4.
Current active and recruiting clinical trials CAR T-cell therapy in metastatic RCC.
| Trial number | Target | Agent(s) | Setting | Primary outcome measures |
|---|---|---|---|---|
| NCT04969354 | CAIX | CAIX-targeted CAR T cell | Up to 2 prior lines of treatment including anti-PD-1/PD-L1 agents | AEs, ORR |
| NCT04438083 | CD70 | CTX130 | Refractory to all SoC therapies | AEs, ORR |
| NCT04696731 | CD70 | ALLO-316 | Refractory to prior ICI and VEGF-TKI | DLT |
| NCT05420519 | CD70 | CD70–targeted CAR T cell | Refractory to all SoC therapies | AEs, MTD |
| NCT05518253 | CD70 | CD70–targeted CAR T cell | Refractory to all SoC therapies | AEs, MTD |
| NCT05468190 | CD70 | CD70–targeted CAR T cell | Refractory to all SoC therapies | AEs, MTD |
| NCT05420545 | CD70 | CD70–targeted CAR T cell | Refractory to all SoC therapies | AEs, MTD |
| NCT02830724 | CD70 | CD70–targeted CAR T cell | Refractory to at least one line of therapy | AEs, ORR |
| NCT05795595 | CD70 | CTX131 | Refractory to SoC therapies | AEs, ORR |
| NCT03393936 | ROR2 and AXL | CCT301–59 for ROR2, and CCT301–38 for AXL | Refractory to SoC therapies | DLT, ORR |
CAIX = carbonic anhydrase IX, AEs = adverse events, ORR = objective response rate, SoC = standard of care, ICI = immune checkpoint inhibitor, VEGF-TKI = vascular endothelial growth factor tyrosine kinase inhibitor, DLT = dose-limiting toxicities, MTD = maximum tolerated dose.